Efficacy of Bevacizumab (Avastin) in Treatment of Acute NMO Exacerbations
Status:
Completed
Trial end date:
2015-05-01
Target enrollment:
Participant gender:
Summary
This is a phase 1b interventional trial of bevacizumab (Avastin®) to evaluate the
tolerability/safety and preliminary efficacy of bevacizumab (Avastin®) as add-on therapy for
treatment of acute optic neuritis and/or transverse myelitis in neuromyelitis optica (NMO)
and neuromyelitis optica spectrum disorder (NMOSD). A single infusion of Avastin® is added to
standard-of-care high dose steroids and an additional dose of Avastin® is added to plasma
exchange (if necessary). The primary outcomes are clinical changes in the Expanded Disability
Severity Scale, Timed 25-foot Walk and Low Contrast Visual Acuity, MRI parameters and safety.
Phase:
Phase 1
Details
Lead Sponsor:
Johns Hopkins University
Collaborators:
Genentech, Inc. Guthy Jackson Charitable Foundation